Ongoing and new developments in chimeric antigen receptor (CAR) T-cell therapies were covered at the 63rd American Society of Hematology (ASH) annual meeting. Coming into the 2021 American Society of ...
Clinical trial results in the leukemia and lymphoma space were covered at the 63rd American Society of Hematology (ASH) annual meeting. The classic chemotherapy regimen known as R-CHOP may get an ...
The 63rd American Society of Hematology Annual Meeting and Exposition will take place virtually and in person Dec. 11–14 in Atlanta, Georgia SEATTLE — Nov. 18, 2021 — How to resolve disparities in ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its extensive hematology portfolio will be ...
In the phase 2 ZUMA-2 study, KTE-X19 CAR-T therapy showed a lasting clinical benefit and manageable side effects in relapsed/refractory mantle cell lymphoma. Researchers sought to determine whether ...
As the third player to enter the BTK realm, BeiGene has had its eyes fixated on AbbVie and Johnson & Johnson’s market leader Imbruvica. After clinical wins in smaller indications, the Chinese-American ...
ASH: Roche's Polivy set to unlock $2B market in newly diagnosed lymphoma with practice-changing data
The guessing is over. Roche has detailed new Polivy data that could change nearly two decades of treatment standards in newly diagnosed lymphoma—while opening up a blockbuster opportunity. In ...
Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab Data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results